Trial Profile
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3F8 I-131 (Primary)
- Indications Astrocytoma; CNS cancer; Ependymoma; Glioma; Malignant melanoma; Medulloblastoma; Meningeal carcinomatosis; Neuroblastoma; Retinoblastoma; Rhabdoid tumour; Sarcoma; Small cell lung cancer
- Focus Therapeutic Use
- 01 Feb 2023 Status changed from active, no longer recruiting to completed.
- 28 Oct 2021 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.
- 02 Oct 2021 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.